以T淋巴母细胞淋巴瘤为首发表现的慢性髓系白血病1例报道
摘要
<正>慢性髓系白血病(chronic myeloid leukemia,CML)是一种发生在多能造血干细胞的恶性骨髓增殖性肿瘤,主要涉及髓系。外周血粒细胞显著增多且不成熟,在受累的细胞系中,存在Ph染色体和(或)BCR/ABL1融合基因。该基因由9号染色体长臂上C-ABL原癌基因易位至22号染色体长
引文
1 Melo JV,Vardiman JW,Baccarani M,et al.Chronic myelogenous leukemia,BCR-ABL1-positive[M]//Swerdlow SH,Campo E,Harris NL,et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.4th ed.Lyon:IARC Press,2017:30-36.
2 Tsukamoto S,Ota S,Ohwada C,et al.Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation[J].Leuk Res Rep,2013,2(2):67-69.
3 Ichinohasama R,Miura I,Takahashi N,et al.Ph-negative nonHodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis:report of two cases and review of the literature[J].Leukemia,2000,14(1):169-182.
4 Wu JY,Huang L,Zhou JF,et al.Expression of BCR/ABL fusion gene in circulating endothelial cells from chronic myelogenous leukemia patients and its clinical significance[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2014,22(4):927-931.
5 Gao X,Li J,Wang L,et al.Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia:A Case Report and Literature Review[J].Am J Case Rep,2016,17:793-798.
6 Qing X,Qing A,Ji P,et al.Mixed phenotype(T/B/myeloid)extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia[J].Exp Mol Pathol,2018,104(2):130-133.
7 Luatti S,Castagnetti F,Marzocchi G,et al.Additional chromosomal abnormalities in Philadelphia-positive clone:adverse prognostic influence on frontline imatinib therapy:a GIMEMA Working Party on CML analysis[J].Blood,2012,120(4):761-767.
8 Baccarani M,Deininger MW,Rosti G,et al.European LeukemiaNet recommendations for the management of chronic myeloid leukemia:2013[J].Blood,2013,122(6):872-884.
9 de Oliveira FM,de Carvalho Palma L,Falc?o RP,et al.A new dic(7;12)(p12.21;p12.2)and i(12)(q10)during the lymphoid blast crisis of patient with Ph+chronic myeloid leukemia[J].Med Oncol,2012,29(4):2332-2336.
10 Baccarani M,Saglio G,Goldman J,et al.Evolving concepts in the management of chronic myeloid leukemia:recommendations from an expert panel on behalf of the European LeukemiaNet[J].Blood,2006,108(6):1809-1820.
11 Cortes JE,Talpaz M,O'Brien S,et al.Staging of chronic myeloid leukemia in the imatinib era:an evaluation of the World Health Organization proposal[J].Cancer,2006,106(6):1306-1315.
12岳延华,何雪峰,潘金兰,等.附加染色体异常对慢性髓系白血病慢性期患者酪氨酸激酶抑制剂疗效的影响[J].中国实验血液学杂志,2018,26(5):1275-1280.
13 Baccarani M,Cortes J,Pane F,et al.Chronic myeloid leukemia:an update of concepts and management recommendations of European LeukemiaNet[J].J Clin Oncol,2009,27(35):6041-6051.
14 Schoch C,Haferlach T,Kern W,et al.Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate[J].Leukemia,2003,17(2):461-463.
15周箭.258例慢性粒细胞性白血病的临床和实验研究[J].四川医学,2010,31(2):177-179.
16薛志科,金洁,陈志妹,等.135例非单纯Ph染色体的慢性髓系白血病细胞遗传学分析[J].中国实验血液学杂志,2008,16(5):997-1001.
17 Naumann S,Decker HJ.Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia[J].Cancer Genet Cytogenet,2003,147(1):18-22.
18张学亚,吴诗馨,郭熙哲,等.伴变异性Ph染色体阳性白血病临床特点及预后分析[J].中国实验血液学杂志,2018,26(4):1056-1061.
19 Cooley LD,Sears DA,Udden MM,et al.Donor cell leukemia:report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature[J].Am J Hematol,2000,63(1):46-53.
20 Hirata J,Umemura T,Nishimura J,et al.Double t(1;7)(p36;p11)in a megakaryocytic crisis of chronic myelogenous leukemia with variant t(5;9;22)[J].Cancer Genet Cytogenet,1993,65(2):107-110.
21 Nowell PC,Jensen J,Gardner F.Two complex translocations in chronic granulocytic leukemia involving chromosomes 22,9,and a third chromosome[J].Humangenetik,1975,30(1):13-21.
22 Oshimura M,Ohyashiki K,Terada H,et al.Variant Ph1translocations in CML and their incidence,including two cases with sequential lymphoid and myeloid crises[J].Cancer Genet Cytogenet,1982,5(3):187-201.
23 Stopera SA,Ray M,Riordan D,et al.Variant Philadelphia translocations in chronic myeloid leukemia:correlation with cancer breakpoints,fragile sites and oncogenes[J].Cancer Lett,1990,55(3):249-253.
24仇海荣,缪扣荣,钱思轩,等.362例慢性髓系白血病的细胞遗传学分析[J].中国实验血液学杂志,2009,17(1):27-30.
25 Al-Achkar W,Wafa A,Nweder MS.A complex translocation t(5;9;22)in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia[J].J Exp Clin Cancer Res,2007,26(3):411-415.
26 Balatzenko G,Grudeva-Popova J,Krustev T,et al.Philadelphia variant,t(5;9;22)(q13;q34;q11),in a case with chronic myeloid leukemia[J].J BUON,2003,8(1):65-67.
27 Jabbour EJ,Hughes TP,Cortés JE,et al.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia[J].Leuk Lymphoma,2014,55(7):1451-1462.
28 Saglio G,Hochhaus A,Goh YT,et al.Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2years of follow-up in a phase 3 study:efficacy and tolerability of 140milligrams once daily and 70 milligrams twice daily[J].Cancer,2010,116(16):3852-3861.
29 Giles FJ,Kantarjian HM,le Coutre PD,et al.Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase[J].Leukemia,2012,26(5):959-962.
2 Tsukamoto S,Ota S,Ohwada C,et al.Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation[J].Leuk Res Rep,2013,2(2):67-69.
3 Ichinohasama R,Miura I,Takahashi N,et al.Ph-negative nonHodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis:report of two cases and review of the literature[J].Leukemia,2000,14(1):169-182.
4 Wu JY,Huang L,Zhou JF,et al.Expression of BCR/ABL fusion gene in circulating endothelial cells from chronic myelogenous leukemia patients and its clinical significance[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2014,22(4):927-931.
5 Gao X,Li J,Wang L,et al.Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia:A Case Report and Literature Review[J].Am J Case Rep,2016,17:793-798.
6 Qing X,Qing A,Ji P,et al.Mixed phenotype(T/B/myeloid)extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia[J].Exp Mol Pathol,2018,104(2):130-133.
7 Luatti S,Castagnetti F,Marzocchi G,et al.Additional chromosomal abnormalities in Philadelphia-positive clone:adverse prognostic influence on frontline imatinib therapy:a GIMEMA Working Party on CML analysis[J].Blood,2012,120(4):761-767.
8 Baccarani M,Deininger MW,Rosti G,et al.European LeukemiaNet recommendations for the management of chronic myeloid leukemia:2013[J].Blood,2013,122(6):872-884.
9 de Oliveira FM,de Carvalho Palma L,Falc?o RP,et al.A new dic(7;12)(p12.21;p12.2)and i(12)(q10)during the lymphoid blast crisis of patient with Ph+chronic myeloid leukemia[J].Med Oncol,2012,29(4):2332-2336.
10 Baccarani M,Saglio G,Goldman J,et al.Evolving concepts in the management of chronic myeloid leukemia:recommendations from an expert panel on behalf of the European LeukemiaNet[J].Blood,2006,108(6):1809-1820.
11 Cortes JE,Talpaz M,O'Brien S,et al.Staging of chronic myeloid leukemia in the imatinib era:an evaluation of the World Health Organization proposal[J].Cancer,2006,106(6):1306-1315.
12岳延华,何雪峰,潘金兰,等.附加染色体异常对慢性髓系白血病慢性期患者酪氨酸激酶抑制剂疗效的影响[J].中国实验血液学杂志,2018,26(5):1275-1280.
13 Baccarani M,Cortes J,Pane F,et al.Chronic myeloid leukemia:an update of concepts and management recommendations of European LeukemiaNet[J].J Clin Oncol,2009,27(35):6041-6051.
14 Schoch C,Haferlach T,Kern W,et al.Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate[J].Leukemia,2003,17(2):461-463.
15周箭.258例慢性粒细胞性白血病的临床和实验研究[J].四川医学,2010,31(2):177-179.
16薛志科,金洁,陈志妹,等.135例非单纯Ph染色体的慢性髓系白血病细胞遗传学分析[J].中国实验血液学杂志,2008,16(5):997-1001.
17 Naumann S,Decker HJ.Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia[J].Cancer Genet Cytogenet,2003,147(1):18-22.
18张学亚,吴诗馨,郭熙哲,等.伴变异性Ph染色体阳性白血病临床特点及预后分析[J].中国实验血液学杂志,2018,26(4):1056-1061.
19 Cooley LD,Sears DA,Udden MM,et al.Donor cell leukemia:report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature[J].Am J Hematol,2000,63(1):46-53.
20 Hirata J,Umemura T,Nishimura J,et al.Double t(1;7)(p36;p11)in a megakaryocytic crisis of chronic myelogenous leukemia with variant t(5;9;22)[J].Cancer Genet Cytogenet,1993,65(2):107-110.
21 Nowell PC,Jensen J,Gardner F.Two complex translocations in chronic granulocytic leukemia involving chromosomes 22,9,and a third chromosome[J].Humangenetik,1975,30(1):13-21.
22 Oshimura M,Ohyashiki K,Terada H,et al.Variant Ph1translocations in CML and their incidence,including two cases with sequential lymphoid and myeloid crises[J].Cancer Genet Cytogenet,1982,5(3):187-201.
23 Stopera SA,Ray M,Riordan D,et al.Variant Philadelphia translocations in chronic myeloid leukemia:correlation with cancer breakpoints,fragile sites and oncogenes[J].Cancer Lett,1990,55(3):249-253.
24仇海荣,缪扣荣,钱思轩,等.362例慢性髓系白血病的细胞遗传学分析[J].中国实验血液学杂志,2009,17(1):27-30.
25 Al-Achkar W,Wafa A,Nweder MS.A complex translocation t(5;9;22)in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia[J].J Exp Clin Cancer Res,2007,26(3):411-415.
26 Balatzenko G,Grudeva-Popova J,Krustev T,et al.Philadelphia variant,t(5;9;22)(q13;q34;q11),in a case with chronic myeloid leukemia[J].J BUON,2003,8(1):65-67.
27 Jabbour EJ,Hughes TP,Cortés JE,et al.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia[J].Leuk Lymphoma,2014,55(7):1451-1462.
28 Saglio G,Hochhaus A,Goh YT,et al.Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2years of follow-up in a phase 3 study:efficacy and tolerability of 140milligrams once daily and 70 milligrams twice daily[J].Cancer,2010,116(16):3852-3861.
29 Giles FJ,Kantarjian HM,le Coutre PD,et al.Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase[J].Leukemia,2012,26(5):959-962.